Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Poster Session B

Imaging

Session: (1033–1051) Imaging of Rheumatic Diseases Poster I

1051: Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology: Interim Analysis

Monday, November 13, 2023
9:00 AM – 11:00 AM PT
Location: Poster Hall
On Demand In Person

    Abstract Poster Presenter(s)

  • Sibel Aydin, MD

    University of Ottawa - Ottawa
    Ottawa, ON, Canada

    Disclosure(s): abbvie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); clarius: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); fresenius Kabi: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); UCB: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

sibel aydin1, seyyid acikgoz2, Ummugulsum Oguz3, antonio Vieira4, patrick Leclerc4, Suharsh Shah4, Lihi Eder5 and Gurjit S Kaeley6, 1University of Ottawa - Ottawa, Ottawa, ON, Canada, 2University of Ottawa, Rheumatology, Ottawa, ON, Canada, 3University of Ottawa, Ottawa, ON, Canada, 4Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada, 5Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 6University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL

Background/Purpose: Ultrasonography (US) has experienced a rapid evolution in rheumatology. Despite many advantages being shown repeatedly, several barriers persist and stand in the way of a wider use of US in rheumatology, equipment cost being an important one. Hand-held US technology promises to take this cost down substantially. However, before it can be specifically used for rheumatology, its performance needs to be validated against gold-standard devices for key interventions. We aim to test the concurrent validity of a handheld US device versus a gold-standard device to detect characteristic features of healthy and rheumatic joints (i.e., anatomical structures and vascular flow).

Methods: Adult patients with peripheral PsA presenting with at least one tender and swollen joint were included. Each patient had consecutive US examinations using a handheld (Clarius Mobile Health Inc, HD3 L20 and L15 scanners) and a gold standard US device (GE LogicE9) for detecting synovitis, nail disease, and erosions. B mode and power Doppler images were saved for each site and lesion. Every image was given a unique identifier number at the end. Image reading was performed at least 2 weeks after the acquisition of US in all patients. A random order slide show was conducted for scoring, irrespective of the machine used or the anatomical site or patient assessed, to ensure blindness. Scoring was done using previously validated methods. Here we present interim analysis for the first 10 patients to detect synovitis (n=240), nail disease (n=20), and erosions (n=40).

Results: Patients had a mean±SD age of 55.2±8.6, with a median (IQR) disease duration of 7(12) years. 40% were female. On the day of the US, the median (IQR tender joint count was 8.5(18.5) and swollen joint count was 4.5(5.75).At least moderate agreement was observed between the handheld and gold standard devices in all elementary lesions assessed (table). Specifically, both detecting synovitis, the L15 and L20, had a kappa of 0.499 and 0.535 compared to the GE machine, respectively, with absolute agreement rates of 76.7-77.8%. For detecting the intrasynovial Doppler signals, the L15 had a substantial agreement (kappa: 0.667, absolute agreement: 93.9%); and L20 had moderate agreement (kappa: 0.428, absolute agreement: 89.3%). The nail lesions were compared with L20, which showed a moderate agreement to detect the loss of trilaminar appearance (kappa: 0.490, absolute agreement: %75) and substantial agreement to detect nail bed vascularity (kappa: 0.732, absolute agreement: 89.5%). For erosions, there was an almost perfect agreement with the L15 (kappa: 0.876, absolute agreement: 94.1%) and moderate agreement with L20 (kappa: 0.486, absolute agreement: 77.5%). Investigating the individual discrepancies, the L20 seemed to be more sensitive to detecting erosions (fig).

Conclusion: In this interim analysis, the handheld US devices show moderate-substantial agreement to detect synovitis, nail lesions and erosions, and Doppler signals. The final analysis will be conducted after 30 PsA patients are enrolled, and enthesitis will also be analyzed. These interim results encourage testing the use of handheld US devices for wider use.


Table: The frequency, kappa and percent absolute agreement of elementary lesions on all three devices.


Figure: Lateral view of the same 2nd MCP joint. A) Longitudinal view using GE LogicE9, with no erosions; B) Longitudinal view using the L20 scanner, showing the erosion (arrow); C) transverse view of the erosion with L20 scanner.


s. aydin: AbbVie/Abbott, 6, Celgene, 6, Clarius, 11, Novartis, 6, Pfizer, 6, UCB, 6; s. acikgoz: None; U. Oguz: None; a. Vieira: Novartis, 3; p. Leclerc: Novartis, 3; S. Shah: Novartis, 3; L. Eder: AbbVie, 2, 5, Eli Lilly, 2, 5, Fresenius Kabi, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, Sandoz, 5, UCB, 2, 5; G. S Kaeley: Abbvie, 5, Gilead, 5, Janssen, 5.